IgG, IgM, and IgA production by purified adult PB CD27+, CD27−, and CB B cells
| . | Adult PB CD27+ B cells . | Adult PB CD27− B cells . | CB B cells . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IgG (ng/mL) . | IgM (ng/mL) . | IgA (ng/mL) . | IgG (ng/mL) . | IgM (ng/mL) . | IgA (ng/mL) . | IgG (ng/mL) . | IgM (ng/mL) . | IgA (ng/mL) . | |
| Medium | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 |
| SAC* + IL-2* | 8960 ± 3015‡ | 6938 ± 2509 | 7533 ± 2340 | < 62 | < 62 | < 62 | < 62 | 487 ± 123 | < 62 |
| IL-10* + CD40*/CD32T† | 1966 ± 492 | 1935 ± 604 | 2054 ± 612 | < 62 | < 62 | < 62 | < 62 | 185 ± 55 | < 62 |
| SAC + IL-2 + IL-10 + CD40/CD32T | 9980 ± 3436 | 9257 ± 3350 | 9918 ± 2685 | 4643 ± 1336 | 4569 ± 1453 | < 62 | 6430 ± 1908 | 6225 ± 1911 | < 62 |
| . | Adult PB CD27+ B cells . | Adult PB CD27− B cells . | CB B cells . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IgG (ng/mL) . | IgM (ng/mL) . | IgA (ng/mL) . | IgG (ng/mL) . | IgM (ng/mL) . | IgA (ng/mL) . | IgG (ng/mL) . | IgM (ng/mL) . | IgA (ng/mL) . | |
| Medium | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 | < 62 |
| SAC* + IL-2* | 8960 ± 3015‡ | 6938 ± 2509 | 7533 ± 2340 | < 62 | < 62 | < 62 | < 62 | 487 ± 123 | < 62 |
| IL-10* + CD40*/CD32T† | 1966 ± 492 | 1935 ± 604 | 2054 ± 612 | < 62 | < 62 | < 62 | < 62 | 185 ± 55 | < 62 |
| SAC + IL-2 + IL-10 + CD40/CD32T | 9980 ± 3436 | 9257 ± 3350 | 9918 ± 2685 | 4643 ± 1336 | 4569 ± 1453 | < 62 | 6430 ± 1908 | 6225 ± 1911 | < 62 |
IgG, IgM, and IgA production assays, using 2.5 × 104 to 105 per well of highly purified adult PB CD27+, CD27−, and CB B cells, were performed as described in “Materials and methods.”
The final concentrations of SAC, IL-2, IL-10, and anti-CD40 were 0.01%, 50 U/mL, 50 ng/mL, and 1 μg/mL, respectively.
The transfectants accounted for 40% of the number of B cells added.
Results are expressed as the mean ± SD of triplicate experiments.